Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Hematide: Phase II data

In an open-label Phase II trial, the primary endpoint of achieving Hb >11 g/dL without transfusion was

Read the full 176 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE